In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on Eton Pharmaceuticals (ETON), with a price target of $12.00. The company’s shares closed last Friday at $4.36.
According to TipRanks.com, D’silva is a 1-star analyst with an average return of -3.6% and a 33.5% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals, EyePoint Pharmaceuticals, and Sensus Healthcare.
Eton Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $19.00, implying a 441.3% upside from current levels. In a report issued on March 19, H.C. Wainwright also reiterated a Buy rating on the stock with a $23.00 price target.
See today’s analyst top recommended stocks >>
Based on Eton Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $459K and GAAP net loss of $2.7 million. In comparison, last year the company had a GAAP net loss of $3.73 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. Its portfolio consists of injectable, oral liquid, ophthalmic products pipelines. The company was founded in April 2017 and is headquartered in Deer Park, IL.
